Fortrea’s first quarter results were met with a negative market reaction, reflecting ongoing operational challenges despite revenue and profit coming in above Wall Street expectations. Management attributed the revenue decline primarily to slower project starts and a heavier mix of complex, longer-duration oncology studies, which tend to progress more slowly. CEO Tom Pike explained that "book-to-bill was 1.02 times for the quarter," signaling a pipeline that is solid but sensitive to delays in biotech decision-making and funding. CFO Jill McConnell also noted that while cost-cutting initiatives have reduced headcount by over 8% year-over-year, SG&A expenses remain above industry peers due to the lingering impacts of Fortrea’s recent spin-off.

Is now the time to buy FTRE? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Fortrea’s Q1 Earnings Call

• David Windley (Jefferies) asked about the cadence of revenue and margin improvement for the remainder of the year. CFO Jill McConnell clarified that first quarter revenue strength was largely due to higher pass-through in Clinical Pharmacology, which may not persist, and that margin gains will be more pronounced in the second half as cost initiatives ramp.
• Justin Bowers (DB) questioned the outlook for Clinical Pharmacology bookings and pricing. CEO Tom Pike responded that while bookings were softer in the quarter, the pipeline has since strengthened and the business remains a strong contributor, with efforts ongoing to optimize pricing and capacity.
• Patrick Donnelly (Citi) inquired about competitive dynamics and pricing discipline in light of increased biotech caution and large CROs entering the space. Pike explained that competition has increased, but pricing remains disciplined and the pipeline is “solid.”
• Charles Rhyee (TD Cowen) asked about the impact of biotech funding challenges on project timelines and receivables. Pike and McConnell noted that delays in decision-making are evident but cancellations have not increased; rigorous booking criteria are used to mitigate credit risk.
• Matt Sykes (Goldman Sachs) pressed on the achievability of a 1.2x book-to-bill target amid macro uncertainty. Pike acknowledged that while the path exists, delivering on this target depends on factors outside Fortrea’s control, including regulatory and funding developments.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will focus on (1) the pace at which cost reduction programs translate into lower SG&A and improved operating margins, (2) whether biotech project pipelines continue to convert to revenue amid funding headwinds, and (3) the impact of digital tools and automation on project delivery efficiency. We will also track progress on the CEO succession and stabilization of backlog burn rates.

Fortrea currently trades at $5, down from $6.16 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.